US Patent Issued to Novartis on Feb. 17 for "Methods of treating chronic inflammatory disease with secukinumab" (Swiss, German Inventors)

ALEXANDRIA, Va., Feb. 17 -- United States Patent no. 12,551,554, issued on Feb. 17, was assigned to Novartis AG (Basel, Switzerland).

"Methods of treating chronic inflammatory disease with secukinumab" was invented by Achim Guettner (Binzen, Germany), Matthias Machacek (Allschwil, Switzerland), Charis Papavassilis (Loerrach, Germany) and Oliver Sander (Basel, Switzerland).

According to the abstract* released by the U.S. Patent & Trademark Office: "The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor anti...